OrbiMed’s Kenvue KVUE Stock Holding History

OrbiMed’s Portfolio KVUE Stock Details KVUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-312,404	Closed	-$6.27M	–	126
2023 Q3	$6.27M	Buy	+312,404	New	+$7.23M	0.13%	95

Other funds holding KVUE

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed's KVUE Position: Q4 2023 in Review

OrbiMed sold out of Kenvue (KVUE) in Q4 2023, closing a stake of 312,404 shares — an estimated $6.27M sold.

OrbiMed first reported a position in KVUE in Q3 2023 and held it in 1 quarter. The position peaked at $6.27M in Q3 2023. 983 funds tracked by Wall St. Rank hold KVUE as of Q4 2023.

OrbiMed reported no remaining Kenvue position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 312,404 Kenvue shares in Q4 2023, an estimated $6.27M.
OrbiMed first reported a position in Kenvue in Q3 2023 and held it in 1 quarter.
OrbiMed's Kenvue position peaked at $6.27M in Q3 2023.
983 funds tracked by Wall St. Rank held Kenvue as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.